Gain Therapeutics Inc
GANX
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.64M
Close$
$0.61
65.2% downside
Current Fair Value
65.2% downsideOvervalued by 65.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $74.64 Million |
|---|---|
| Enterprise Value | $62.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.61 |
| Beta | 0.21 |
| Outstanding Shares | 42,879,541 |
Return
| Return on Equity | -178.06% |
|---|---|
| Return on Assets | -130.37% |
| Return on Invested Capital | -159.54% |
Valuation & Multiples
| P/E Ratio | -3.5 |
|---|---|
| PEG | 17.94 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.25 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$33,333
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$33,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3210▼ 2.25% |
|---|---|
| Total Calls | 111,200▲ 21.66% |
| Total Puts | 35,700▲ 13.69% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.20%▲ 0.79% |
|---|---|
| Total Invested | $17.40M▲ 9.95% |
| Investors Holding | 54▲ 8.00% |
ESG Score
No data
About Gain Therapeutics Inc
16 employeesGain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...